Presentation is loading. Please wait.

Presentation is loading. Please wait.

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.

Published byHelen Caldwell Modified over 6 years ago

Similar presentations

Presentation on theme: "Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko."— Presentation transcript:

1 Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib 
Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko Inamasu, MD, Tsukihisa Yoshida, MD, Kaname Nosaki, MD, Tomoyoshi Takenaka, MD, PhD, Masafumi Yamaguchi, MD, PhD, Takashi Seto, MD, PhD, Mitsuhiro Takenoyama, MD, PhD, Yukito Ichinose, MD, PhD  Journal of Thoracic Oncology  Volume 9, Issue 12, Pages e86-e87 (December 2014) DOI: /JTO Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Direct sequencing by capillary electrophoresis of a biopsy sample obtained from the left clavicle before crizotinib treatment using an ABI PRISM 310 Genetic Analyzer (A). Computed tomography scans showed metastatic mediastinal lymph nodes before (B) and approximately 7 months after the administration of crizotinib (C). There was expansion of the pleural effusion with no relapse of the mediastinal lymph nodes (D). Direct sequencing of a biopsy sample of pleural effusion after a relapse on crizotinib identified a secondary mutation of the ALK gene at codon 1171 (I1171T) (E). Journal of Thoracic Oncology 2014 9, e86-e87DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Direct sequencing by capillary electrophoresis of a biopsy sample obtained from the skin metastasis before the administration of alectinib using an ABI PRISM 310 Genetic Analyzer (A). Computed tomography scans showing the primary lesion in the right lower lobe and hepatic metastases before (B) and approximately 4 months after (C) the administration of alectinib. A computed tomography scan indicating the relapse of the primary lesion and hepatic metastases approximately 7 months after the administration of alectinib (D). Direct sequencing of a biopsy sample obtained from the hepatic metastasis after a relapse on alectinib showing a secondary mutation of the ALK gene at codon 1171 (I1171N) (E). Journal of Thoracic Oncology 2014 9, e86-e87DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko."

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.
Lungs on Fire Journal of Thoracic Oncology

Lungs on Fire Journal of Thoracic Oncology
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
Dramatic Response to Crizotinib in an ALK-Positive Adenocarcinoma Patient with Disseminated Intravascular Coagulation  Gouji Toyokawa, MD, PhD, Mitsuhiro.

Dramatic Response to Crizotinib in an ALK-Positive Adenocarcinoma Patient with Disseminated Intravascular Coagulation  Gouji Toyokawa, MD, PhD, Mitsuhiro.
Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802)

Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH /RO )
Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,
MET Mutation Associated with Responsiveness to Crizotinib

MET Mutation Associated with Responsiveness to Crizotinib
Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.
David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F
Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,
Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non– small-cell Lung Cancer Exhibiting Resistance to Ceritinib  Gouji Toyokawa,

Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non– small-cell Lung Cancer Exhibiting Resistance to Ceritinib  Gouji Toyokawa,
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
Victoria Wang, MD, PhD, Trever Bivona, MD, PhD 

Victoria Wang, MD, PhD, Trever Bivona, MD, PhD 

Similar presentations

Ads by Google